Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance

Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $44.87 million.

GUIDANCE:

Adaptive Biotechnologies sees FY2023 revenue of $205-215 million, versus the consensus of $207.2 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Anthropic delays planned IPO from October to November - WSJ
• Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®